Galapagos NV
GLPG
$28.60
Share price
-0.10%
Change (1 day)
-25.46%
Change (1 year)
Categories
Galapagos NV (GLPG) - Cash on Hand
Cash on Hand as of September 2023 : $4.02 B
According to Galapagos NV's latest financial reports the company has $4.02 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Galapagos NV - Cash on Hand chart (from 2008 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $4.38 B | -17.68% |
| 2021-12-31 | $5.32 B | -16.1% |
| 2020-12-31 | $6.34 B | -1.97% |
| 2019-12-31 | $6.47 B | 338.55% |
| 2018-12-31 | $1.47 B | 6.85% |
| 2017-12-31 | $1.38 B | 34.89% |
| 2016-12-31 | $1.02 B | 175.34% |
| 2015-12-31 | $0.37 B | 62.99% |
| 2014-12-31 | $0.22 B | 19.64% |
| 2013-12-31 | $0.19 B | 52.42% |
| 2012-12-31 | $0.12 B | 196.73% |
| 2011-12-31 | $42.19 M | -21.48% |
| 2010-12-31 | $53.73 M | -20.86% |
| 2009-12-31 | $67.89 M | 77.8% |
| 2008-12-31 | $38.18 M | -46.94% |
| 2007-12-31 | $71.97 M | 5.69% |
| 2006-12-31 | $68.1 M | 144.02% |
| 2005-12-31 | $27.9 M | 100.25% |
| 2004-12-31 | $13.93 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $22.92 B | 469.31% | 🇺🇸 USA |
 Abbott Laboratories ABT | $7.27 B | 80.75% | 🇺🇸 USA |
 AbbVie ABBV | $12.81 B | 218.24% | 🇺🇸 USA |
 Sanofi SNY | $9.92 B | 146.53% | 🇫🇷 France |
 Merck MRK | $7.09 B | 76.13% | 🇺🇸 USA |
 AstraZeneca AZN | $5.86 B | 45.51% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $6.35 B | 57.80% | 🇬🇧 UK |
 Fortress Biotech
FBIO | $72.3 M | -98.20% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $3.22 B | -19.89% | 🇮🇱 Israel |